Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of HAL-MRE1 Subcutaneous Immunotherapy in Adult Subjects With Ragweed Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Conditions
Interventions
HAL-MRE1
Locations
1
Canada
Inflamax Research Inc.
Mississauga, Canada
Start Date
November 21, 2018
Primary Completion Date
May 17, 2019
Completion Date
May 17, 2019
Last Updated
August 6, 2019
NCT04435990
NCT06427577
NCT07427576
NCT06741800
NCT00779545
NCT00127647
Lead Sponsor
HAL Allergy
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions